Lipid clinic experience with bempedoic acid in three UK centres-Reference-Cited by-同舟云学术

Lipid clinic experience with bempedoic acid in three UK centres

Published:2024-04-25 Issue:6 Volume:40 Page:911-916
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Jakubowska Agnieszka¹,Al Hasani Wiaam²,Williams Jamal²,MacMahon Zofia²,Balbas Bryan²,Crook Martin A.²,Viljoen Adie¹,Reynolds Timothy M.³,Wierzbicki Anthony S.²

Affiliation:

1. Department of Metabolic Medicine/Chemical Pathology, East Hertfordshire NHS Foundation Trust (Lister Hospital), Stevenage, UK

2. Department of Metabolic Medicine/Chemical Pathology, Guy’s & St Thomas’ Hospitals, London, UK

3. Department of Metabolic Medicine/Chemical Pathology, Queen’s Hospital, Burton-on-Trent, UK

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2341870

Reference29 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

2. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

4. National Clinical Guideline Centre. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline [NG238]. London, UK: National Institute for Health and Care Excellence; 2023.

5. Role of Bempedoic Acid in Clinical Practice